[
    [
        {
            "time": "",
            "original_text": "华东医药(000963.SZ)首次海外授权！口服GLP-1创新药TTP273进军韩国市场",
            "features": {
                "keywords": [
                    "华东医药",
                    "海外授权",
                    "GLP-1",
                    "创新药",
                    "TTP273",
                    "韩国市场"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "创新药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药(000963.SZ)首次海外授权！口服GLP-1创新药TTP273进军韩国市场",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "华东医药：子公司与DaeWon签署产品独家授权许可协议",
            "features": {
                "keywords": [
                    "华东医药",
                    "子公司",
                    "DaeWon",
                    "独家授权",
                    "许可协议"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "国际合作",
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：子公司与DaeWon签署产品独家授权许可协议",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药最新公告：子公司奥硝唑片通过仿制药一致性评价",
            "features": {
                "keywords": [
                    "华东医药",
                    "子公司",
                    "奥硝唑片",
                    "仿制药",
                    "一致性评价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "仿制药",
                    "一致性评价"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药最新公告：子公司奥硝唑片通过仿制药一致性评价",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药(000963.SZ)：奥硝唑片通过仿制药质量和疗效一致性评价",
            "features": {
                "keywords": [
                    "华东医药",
                    "奥硝唑片",
                    "仿制药",
                    "质量和疗效",
                    "一致性评价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "仿制药",
                    "一致性评价"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药(000963.SZ)：奥硝唑片通过仿制药质量和疗效一致性评价",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药奥硝唑片通过一致性评价 强化抗感染类产品线市场竞争",
            "features": {
                "keywords": [
                    "华东医药",
                    "奥硝唑片",
                    "一致性评价",
                    "抗感染类",
                    "市场竞争"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "仿制药",
                    "抗感染类药物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药奥硝唑片通过一致性评价 强化抗感染类产品线市场竞争",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药：中美华东与DaeWon签署产品独家授权许可协议",
            "features": {
                "keywords": [
                    "华东医药",
                    "中美华东",
                    "DaeWon",
                    "独家授权",
                    "许可协议"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "国际合作",
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：中美华东与DaeWon签署产品独家授权许可协议",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]